The Energy Ledger: Four Peptides, One Cellular-Metabolism Frame

The short version

Peptide Batteries is a research digest built around one question: what does each peptide actually do to how cells make and use energy? The four compounds on this site work in very different ways — one is a signal built from a gene sequence inside the mitochondria (the part of the cell that produces energy), one is a copper-carrying repair molecule, and two are engineered hormone look-alikes that change how the body handles blood sugar and appetite. 'Cellular energy' here doesn't mean a caffeine pitch — it means the actual biochemistry: how a cell senses fuel, activates AMPK (a kind of low-fuel alarm switch), or shifts insulin and glucagon signaling. This site reads the published research — trial numbers, mechanisms, effect sizes — and reports it plainly, with a number in brackets, like ^[6], pointing to the exact source on the references page. Nothing here is a dose recommendation, and nothing here is sold.

Cellular energy and metabolism, across four peptide classes

Four peptides, one frame, and one honest caveat: the fit isn't uniform. MOTS-c is the tightest match and this site's lead compound — a 16-amino-acid peptide encoded inside mitochondrial DNA, whose best-documented action is inhibiting the folate cycle to activate AMPK, the enzyme that functions as a cell's low-fuel alarm ^[8][11]. Tirzepatide and retatrutide sit squarely in metabolic regulation too, from a different angle: both engage the GIP and GLP-1 receptors to change glucose-dependent insulin secretion, and retatrutide adds a third receptor, glucagon, specifically to raise energy expenditure rather than just cut appetite ^[12].

GHK-Cu is the outlier, and this desk says so plainly rather than force a fit. Its best-documented mechanism is tissue and collagen remodeling in skin and hair, not energy metabolism ^[1][4]. It earns a place on this frame only at the edges — through the antioxidant and redox gene programs its broad transcriptomic signature switches on ^[2] — and its page is written accordingly, without stretching dermatology data into an energy-metabolism claim it doesn't support.

What are research peptides?

Peptides are short chains of amino acids — smaller than proteins, built from the same twenty building blocks. The four compounds here span very different peptide categories: MOTS-c is a mitochondrial-derived peptide, translated from a short reading frame inside the cell's own mitochondrial genome rather than the nuclear one ^[11]. GHK-Cu is a naturally occurring tripeptide (three amino acids) that binds a copper ion. Tirzepatide and retatrutide are synthetic, 39-amino-acid peptides engineered from the natural GIP hormone backbone, with a fatty-acid chain attached so the body's own albumin protein carries them and slows their clearance, allowing once-weekly dosing in the trials that tested them.

Two of the four — tirzepatide, approved, and retatrutide, pending Phase 3 results — are pursued as approved medicines. GHK-Cu's approved use is topical and cosmetic. MOTS-c has no approved human use at all; every number on its page comes from cell or animal studies, or from association studies in humans, not from a completed human drug trial.

How the numbers line up

Reading the four side by side, in the units each was actually measured in: MOTS-c increased treadmill running capacity in aged mice at a p-value of 0.000002 ^[9], and a 94-patient hemodialysis cohort found circulating MOTS-c independently associated with mortality and cardiovascular risk (Cox HR 1.004) ^[7] — a human association, not an interventional trial. Tirzepatide, the only one of the four with a completed head-to-head weight-loss trial, produced a mean -20.2% body-weight change at 72 weeks versus -13.7% for semaglutide (P<0.001) ^[18]. Retatrutide, still investigational, posted -24.2% at 48 weeks against -2.1% for placebo in its Phase 2 obesity trial ^[16], and cut liver fat by -82.4% at 24 weeks in a MASLD substudy ^[15]. GHK-Cu's numbers come from a different kind of study: a 45-patient hair-count trial showed a 52.6-71.5 count increase against 9.6 for placebo ^[3], and topical use raised collagen synthesis in 70% of treated subjects versus 50% for vitamin C ^[4].

Four different units of measurement, four different evidence bases. Read each page for the full trial design before treating any of these figures as comparable.